Diabetes Trials

  1. (194-21) Effect of ziltivekimab in patients with ASCVD and CKD (Phase 3 clinical trial, appropriate for patients with atherosclerotic cardiovascular disease and chronic kidney disease) 
  2. (267-21) Use of the Guardian™ Connect system with Smart Connected Devices (Appropriate for patients with type 1 or type 2 diabetes)
  3. (255-20) A Post Approval Study to Evaluate the Safety and Effectiveness of the Eversense® Continuous Glucose Monitoring (CGM) System Used Nonadjunctively (Post approval study, appropriate for patients with type 1 or type 2 diabetes)
  4. (262-22) A Randomized Trial Evaluating Control-IQ Technology in Adults With Type 2 Diabetes (2IQP)

Your participation in any trial is entirely voluntary. You may decide to withdraw at any time without losing the benefits of your standard medical care. 

To learn more about available clinical trials, please contact us at 949-764-4577 or clinicalresearch@hoag.org.